Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...
BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback